Pharma Case Study: Merck’s $11.5B acquisition of Acceleron
Posted on03 Oct 2021
Comments0
Merck will acquire Acceleron Pharma, Inc. XLRN for $180 per share in cash for an approximate total equity value of $11.5 billion... Read More
Sanofi Bangladesh Limited’s majority stake is acquired by Beximco Pharma, Bangladesh
Beximco Pharmaceuticals Limited, one of leading pharmaceutical company based at Bangladesh, have completed its acquisition of the majority stake (54.6%) in Sanofi... Read More
What are the difference between Wholesaler and Specialty Pharmacy?
Posted on07 Sep 2021
Comments0
There are clear cut difference between the two terms. The wholesalers are the first purchaser of the drug, directly from manufacturer. Specialty... Read More
DRL enters agreement to sell its rights to anti-cancer agent E7777 to Citius Pharma
Dr Reddy’s Laboratories Ltd announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. pursuant to which it sold... Read More
Nucala received USFDA approval to treat chronic rhinosinusitis with nasal polyps
GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) have approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5),... Read More
FDC launches Favipiravir oral suspension to treat mild to moderate cases of COVID-19
Pharma firm FDC Ltd on Monday said it has launched oral suspension of Favipiravir to treat mild to moderate cases of COVID-19... Read More
Sun Pharma launches a special initiative ‘Sunkalp’ for the welfare of doctors
Posted on16 Jul 2021
Comments0
Sun Pharmaceutical Industries launched a special initiative ‘Sunkalp’ for the welfare of doctors, their families and the community. The company stated that... Read More
Insight on Neurogastrx licensing deal with Daewoong Pharmaceutical to Develop Fexuprazan
Neurogastrx, Inc. has entered into an exclusive license agreement with Daewoong Pharmaceutical Co., Ltd., of Seoul, South Korea, for the development and... Read More
Case Study: Strategic Insight of acquisition of Constellation Pharmaceuticals by MorphoSys
Posted on03 Jun 2021
TagsConstellation Pharmaceuticals, MorphoSys AG, pharma deal, pharma strategic deal, strategic management in pharma
Comments0
MorphoSys AG, and Constellation Pharmaceuticals, Inc. announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00... Read More
Amryt’s filed Oleogel-S10 NDA for the treatment of Epidermolysis Bullosa
Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the U.S.... Read More